uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry.
2003 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Hepatitis C Virus (HCV) is the leading cause of chronic liver disease worldwide as well as the primary indication for liver transplantation. More than 3% of the world’s population is chronically infected with HCV and there is an urgent need for effective therapy. NS3 protease, a viral enzyme required for propagation of HCV in humans, is a promising target for drug development in this area. This thesis addresses the design, synthesis and biochemical evaluation of new HCV NS3 protease inhibitors.

The main objective of the thesis was the synthesis of peptide-based protease inhibitors of the bifunctional full-length NS3 enzyme (protease-helicase/NTPase). Three types of inhibitors were synthesized: i) classical serine protease inhibitors with electrophilic C-terminals, ii) product-based inhibitors with a C-terminal carboxylate group, and iii) product-based inhibitors with C-terminal carboxylic acid bioisosteres.

The developmental work included the establishment of an improved procedure for solid-phase peptide synthesis (SPPS) in the N-to-C direction, in contrast to the C-to-N direction of classical SPPS methods. This inverse method facilitated synthesis of the peptides modified at the C-terminal.

The potency of more than seventy newly synthesized inhibitors was assessed in an in vitro assay using the native form of the protease, i.e. the full-length NS3. The structure-activity relationship (SAR) data achieved was different from SAR data obtained from the more widely used truncated NS3 (protease domain) assay, indicating that the helicase domain of NS3 participates in the binding of the inhibitors.

The most potent inhibitors identified in this study contained a C-terminal phenyl acyl sulfonamide moiety, i.e. a carboxylic acid bioisostere. It is concluded that the acyl sulfonamide moiety is a promising P1-P1´ spanning entity, which may have potential for use in the development of more drug-like HCV protease inhibitors.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis , 2003. , p. 79
Series
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 0282-7484 ; 282
Keywords [en]
Pharmaceutical chemistry
Keywords [sv]
Farmaceutisk kemi
National Category
Medicinal Chemistry
Research subject
Medicinal Chemistry
Identifiers
URN: urn:nbn:se:uu:diva-3311ISBN: 91-554-5538-7 (print)OAI: oai:DiVA.org:uu-3311DiVA, id: diva2:162374
Public defence
2003-03-21, Lecturehall B41, BMC, Uppsala, 10:15 (English)
Opponent
Available from: 2003-02-26 Created: 2003-02-26 Last updated: 2018-01-13Bibliographically approved
List of papers
1. An Improved Procedure for N- to C-Directed (Inverse) Solid-Phase Peptide Synthesis
Open this publication in new window or tab >>An Improved Procedure for N- to C-Directed (Inverse) Solid-Phase Peptide Synthesis
Show others...
2000 (English)In: Journal of combinatorial chemistry, ISSN 1520-4766, E-ISSN 1520-4774, Vol. 2, no 5, p. 496-507Article in journal (Refereed) Published
Abstract [en]

A method for solid-phase peptide synthesis in the N- to C-direction that delivers good coupling yields and a low degree of epimerization is reported. The optimized method involves the coupling, without preactivation, of the resin-bound C-terminal amino acid with excess amounts of amino acid tri-tert-butoxysilyl (Sil) esters, using HATU as coupling reagent and 2,4,6-trimethylpyridine (TMP, collidine) as a base. For the amino acids investigated, the degree of epimerization was typically 5%, except for Ser(t-Bu) which was more easily epimerized (ca. 20%). Five tripeptides (AA(1)-AA(2)-AA(3)) with different properties were used as representative model peptides in the development of the synthetic method: Asp-Leu-Glu, Leu-Ala-Phe, Glu-Asp-Val, Asp-Ser-Ile, and Asp-D-Glu-Leu. The study used different combinations of HATU and TBTU as activating agents, N, N-diisopropylethylamine (DIEA) and TMP as bases, DMF and dichloromethane as solvents, and cupric chloride as an epimerization suppressant. The epimerization of AA(2) in the coupling of AA(3) was further reduced in the presence of cupric chloride. However, the use of this reagent also resulted in a decrease in loading onto the resin and significant cleavage between AA(1) and AA(2). Experiments indicated that the observed suppressing effect of cupric chloride on epimerization in the present system merely seemed to be a result of a base-induced cleavage of the oxazolone system, the key intermediate in the epimerization process. Consequently, the cleavages were most pronounced in slow couplings. An improved synthesis of fully characterized amino acid tri-tert-butoxysilyl (Sil) ester hydrochloride building blocks is presented. The amino acid Sil esters were found to be stable as hydrochlorides but not as free bases. Although only a few peptides have been used in this study, we believe that the facile procedure devised herein should provide an attractive alternative for the solid-phase synthesis of short (six residues or less) C-terminally modified peptides, e.g., in library format.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-90139 (URN)10.1021/cc000022h (DOI)11029175 (PubMedID)
Available from: 2003-02-26 Created: 2003-02-26 Last updated: 2017-12-14Bibliographically approved
2. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain
Open this publication in new window or tab >>Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain
Show others...
2001 (English)In: Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, E-ISSN 1090-2120, Vol. 11, no 2, p. 203-206Article in journal (Refereed) Published
National Category
Pharmaceutical Sciences Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-51295 (URN)10.1016/S0960-894X(00)00625-9 (DOI)
Available from: 2006-03-04 Created: 2006-03-04 Last updated: 2018-01-11Bibliographically approved
3. Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase)
Open this publication in new window or tab >>Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase)
Show others...
2002 (English)In: Bioorganic & Medicinal Chemistry, ISSN 0968-0896, E-ISSN 1464-3391, Vol. 10, no 12, p. 3915-22Article in journal (Refereed) Published
National Category
Pharmaceutical Sciences Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-91487 (URN)10.1016/S0968-0896(02)00310-3 (DOI)
Available from: 2004-03-16 Created: 2004-03-16 Last updated: 2018-01-13Bibliographically approved
4. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals
Open this publication in new window or tab >>Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals
Show others...
2003 (English)In: Bioorganic & Medicinal Chemistry, ISSN 0968-0896, E-ISSN 1464-3391, Vol. 11, no 12, p. 2551-2568Article in journal (Refereed) Published
National Category
Pharmaceutical Sciences Natural Sciences
Identifiers
urn:nbn:se:uu:diva-66026 (URN)10.1016/S0968-0896(03)00179-2 (DOI)
Available from: 2006-11-13 Created: 2006-11-13 Last updated: 2018-01-10Bibliographically approved

Open Access in DiVA

fulltext(944 kB)9001 downloads
File information
File name FULLTEXT01.pdfFile size 944 kBChecksum MD5
39229cb59f8da4e145916eb703c93fca1a8a97023255f45972f7f624ae1f81cf2f0afe9b
Type fulltextMimetype application/pdf
Buy this publication >>

Authority records BETA

Johansson, Anja

Search in DiVA

By author/editor
Johansson, Anja
By organisation
Organic Pharmaceutical Chemistry
Medicinal Chemistry

Search outside of DiVA

GoogleGoogle Scholar
Total: 9001 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

isbn
urn-nbn

Altmetric score

isbn
urn-nbn
Total: 1329 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf